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Objective: p73 and p63 are two structural and functional homologs of p53, and their biological functions in cancer
progression have attracted attention due to the presence of variants generated by genetic polymorphisms.
Recently, three single nucleotide polymorphisms (SNPs) in the p63 and p73 genes have been associated with
female reproduction. In the present study, we aimed to evaluate the relationship between these SNPs and ovarian
cancer susceptibility and clinical pathology.
Methods: We genotyped the p63 (rs873330 [Genbank, refSNP ID] T > C [T: original base, C: mutant base]) and p73
(rs4648551 G > A and rs6695978 G > A) SNPs in ovarian cancers and healthy controls and analyzed the distributions
of genotype frequencies to evaluate the association of the genotypes with the risk of ovarian cancer and the
clinicopathological characteristics. Logistic regression models were applied in statistical analyses.
Results: Our research revealed that p73 rs6695978 G > A was significantly associated with ovarian cancer patients.
Women with the A allele were at increased risk of ovarian cancer compared to carriers of the G allele (OR = 1.55;
95% CI:1.07–2.19; P = 0.003). Meanwhile, the at-risk A allele was positively related with the occurrence of mucinous
ovarian cancer (OR = 3.48; 95% CI:1.15-6.83; P = 0.001), low degree of differentiation (OR = 1.87; 95% CI:1.03-3.47;
P = 0.003), lymph node metastasis (OR = 1.69; 95% CI: 1.14-2.75; P = 0.010) and estrogen receptor positive (OR = 2.72;
95% CI: 1.38-4.81; P = 0.002). However, we were unable to find any associations of the polymorphisms in another
two SNPs (rs4648551 G > A, rs873330 T > C) with ovarian cancer risk and clinicopathological parameters.
Conclusions: The p73 rs6695978 G > A polymorphism will serve as a modifier of ovarian cancer susceptibility and
prognosis. Further investigations with large sample sizes and of the mechanistic relevance of p73 polymorphism
will be warranted.
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Ovarian cancer is a serious threat to the lives and health
of women around the world. The incidence rate of ovar-
ian cancer, which varies among ethnic groups and geo-
graphic regions, has increased dramatically in recent
years. In China, there are more than 192,000 women
diagnosed with ovarian cancer, with approximately
114,000 deaths annually. Ovarian cancer has become the
second most common malignancy in Chinese women.* Correspondence: xingshengyang@sdu.edu.cn
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reproduction in any medium, provided the orDespite major advances made in its treatment, ovarian
cancer continues to have the highest fatality of all gyne-
cologic malignancies [1]. Approximately 70% of all ovar-
ian cancers were diagnosed at an advanced stage due to
the difficulty of early diagnosis and widespread intra-
abdominal metastasis. Gene susceptibility has been
reported to potentially play a significant role in ovarian
carcinogenesis [2]. Therefore, identifying predisposing
genes to establish high-risk groups and achieve early
diagnosis may be beneficial to improve the survival rate
of ovarian cancer.
The process of tumor formation and regulation appears
to entail a complex combination of genetic, environmentaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cluding ovarian cancer, have been hypothesized to arise
due to the effect of many low-risk gene variants that col-
lectively increase disease risk [3]. Single nucleotide poly-
morphisms (SNPs) are the most common sequence
variations in the human genome, and they involve only a
single base mutation and can affect coding sequences,
splicing and transcription regulation. SNPs can compre-
hensively reflect genomic hereditary and variation with
large quantity, high density, wide distribution and typical
representation. Therefore, SNPs may play increasingly im-
portant roles in screening for the gene mutations and the
susceptibility to oncogenic factors [4].
The p63 and p73 genes belong to the p53 superfamily
of transcription factors, which contribute to cell cycle
regulation, transactivation and apoptosis in response to
DNA damage [5]. Despite sharing a similar structure
and function, each p53 family member appears to play a
distinct role in tumor suppression and progression.
Interestingly, high levels of certain p63 and p73 isoforms
have been observed in some tumors, suggesting that
these proteins may act as oncogenes rather than classic
tumor suppressor proteins [6-9]. Furthermore, p63 and
p73 genes regulate ovary functions and female germ cell
integrity in humans. The two genes overexpression may
play catalytic roles in ovarian epithelial tumor develop-
ment because both of them can produce synergistic
effects on ovarian tissue malignant transformation and
enhance the tumor invasion ability. The relatively new
Genome-wide association study (GWAS) approach has
investigated hundreds of thousands of genetic variants
across the whole human genome for associations with
cancer [10]. Recently, there has also been mounting evi-
dence that both the p63 and p73 genes play important
roles in human cancer, and their biological behaviors in
cancer progression have been revisited in light of var-
iants generated by genetic polymorphisms. However, lit-
tle is known about how the p63 and p73 polymorphisms
are involved in ovarian cancer susceptibility and clinical
pathology. In particular, three SNPs (rs873330 T > C,
rs4648551 G > A, rs6695978 G > A) located in p63 and
p73 have been confirmed to have a clear enrichment of
specific alleles in infertility and in vitro fertilization
(IVF) patients [11]. Infertility, controlled ovarian hyper-
stimulationmay (COH) may be factors predisposing to
ovarian cancer diseases [12]. Infertility therapies utilize
products, such as IVF, that alter the hormonal balance
and may in theory increase the risk of ovarian tumors.
Children born after IVF therapies seem to have a statisti-
cally elevated risk of cancer [12,13].
Based on these observations between infertility and
ovarian cancer risk, we sought to investigate whether the
p63 and p73 polymorphisms could serve as susceptible
and/or progressive factors in ovarian cancer. To analyzewhether the distributions of their genotype frequencies
are associated with clinicopathological characteristics, we
performed genotyping analyses of p63 (rs873330 T > C)
and p73 (rs4648551 G > A, rs6695978 G > A) in a case–
control study of 308 ovarian cancer cases and 324
healthy controls in a Chinese population.
Materials and methods
Patients and samples
This study involved 308 patients diagnosed with ovarian
cancer in Qilu Hospital (Shandong, China) between
January 2008 and September 2011. All ovarian cancer
cases were classified and assessed according to the
American Joint Committee on Cancer (AJCC) and Inter-
national Federation of Gynecology and Obstetrics (FIGO)
classification, and the pathological types were diagnosed
with epithelial ovarian cancer, germ cell tumor, and sex
gonad stromal tumor using conventional pathological
examination or immunohistochemistry after surgical exci-
sion. The histologic subtypes were classified into serous,
mucinous, endometrioid and mixed/other roughly due to
the detailed ovarian tumor histology data were not avail-
able. The exclusion criteria included reported previous
cancer history and metastasized cancer from other organs.
To illustrate whether the three SNPs in p63 and p73 are
susceptible biomarkers, 324 women from a screening pro-
gram for non-infectious and major diseases conducted
from 2009 to 2010 in the same hospital were included as
the control group in this study. The matching criterions
between the cases and the controls include age, BMI
(body mass index), number liveborn, oral contraceptive
use, cigarette smoking, ovarian cancer family history. For
these two groups, a 1.5 ml whole blood sample was
extracted from each participant and stored at −80°C. Writ-
ten informed consent was signed by each subject, and the
study design was approved by the Ethical Committee of
Shandong University.
DNA extraction
Genomic DNA for all subjects was extracted from whole
blood using the Qiagen blood kit (Chatsworth, CA, USA)
following the manufacturer’s instructions. The DNA con-
centration and purity of each sample were measured
using an ultraviolet spectrophotometer (GE Healthcare,
Piscataway, NJ, USA). The genomic DNA samples were
marked with a specimen No. and stored at −80°C.
SNP genotyping analyses
TaqMan allelic discrimination analyses were performed
according to Applied Biosystems standard protocols
(Applied Biosystems, Carlsbad, CA, USA). The SNPs were
as follows: rs4648551 (C_26892242_10), rs6695978
(C_1210727_10), and rs873330 (C_3208788_10) (Applied
Biosystems Inc. ABI). Each 10 μl reaction was composed
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Man Genotyping Master Mix, ABI, Part No. 4371355),
0.5 μl of probes (rs4648551/ rs6695978/ rs873330, ABI),
and 3.5 μl of DNase-free water. The PCR was performed
according to the following amplification protocol: denatur-
ation at 95°C for 10 min, followed by 50 cycles of 92°C for
15 s and 60°C for 1 min and final annealing and extension
at 60°C for 30 s. The PCR products were analyzed by the
5’ nuclease assay (TaqManW) on the Applied Biosystems
Prism 7900HT Fast-Real-time PCR system using the Ste-
pOne Software Version 2.2 (ABI).
Statistical analyses
As quality control, the genotype and allele frequencies of
rs4648551 G >A, rs6695978 G >A and rs873330 T > C
were calculated using a public statistical Web-tool, http://
www.oege.org/software/hwe-mr-calc.shtml, for Hardy-
Weinberg equilibrium (HWE). A P value > 0.05 was con-
sidered as not deviating from equilibrium according to
population genotype frequencies. Logistic regression mod-
els were established to analyze the distributions of theTable 1 Distributions of select variables (covariate data) in th
equilibrium for the SNPs
Variables Cases, n = 308
Age, year (mean ± SD) 52.90 ± 13.26
Body mass index, kg/m2
< 23 85 (27.6)
23-29 157 (51.0))
≥ 29 66 (21.4)
Number liveborn, n (%)
0 19 (6.2)
1-2 227 (73.7)
≥ 3 62 (20.1)
Oral contraceptive use, n (%)
never 184 (59.7)
1-48 months 55 (17.9)








rs 4648551 χ2 = 22.3; P =0.98
rs 6695978 χ2 = 0.04; P =0.81
rs 873330 χ2 = 0.16; P =0.72
a. There are no statistically significant differences between the two groups in the se
b. P >0.05 indicate genotype distributed frequencies in the cases and controls confthree SNP polymorphisms between the case and control
groups and the clinicopathological characteristics of ovar-
ian cancer. P values and Odds Ratios (ORs) were adjusted
for age, BMI, number liveborn, oral contraceptive use,
cigarette smoking, ovarian cancer family history. All statis-
tical tests were considered significant at a level of P ≤ 0.05.
All statistical analyses in our study were conducted using
SPSS Statistics 16.0 (SPSS Inc. Chicago, IL, USA).
Results
The genotype distribution satisfied the hardy-Weinberg
equilibrium
All ovarian cancer patients and healthy controls were
local women in Shandong Province, China. The average
age of cases and controls were 52.90 ± 13.26 and 49.89 ±
13.48 years, respectively, and the Student’s t test did not
show significant differences between the two groups
(P = 0.082). Furthermore, we did not find statistically sig-
nificant differences between the two groups in other
matching characteristics except ovarian cancer family
history (P = 0.003) (Table 1). A chi-squared test was usede cases and controls and test of the Hardy-Weinberg
Controls, n = 324 P




















χ2 = 0.05; P =0.99
χ2 = 10.19; P =0.85
χ2 = 0.10; P =0.75
lect variables (covariate data) except ovarian cancer family history.
ormed with Hardy-Weinberg genetic equilibrium.
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Weinberg equilibrium. The distributed genotype fre-
quencies of these three SNPs (rs4648551 G>A,
rs6695978 G>A, rs873330 T>C) conformed with Hardy-
Weinberg equilibrium in both the case and control
groups (Table 1), which demonstrated that the popula-
tion in this study reached genetic equilibrium with typ-
ical group representation.
The p73 rs6695978 G > A SNP can enhance susceptibility
to ovarian cancer.
This case–control study included 308 ovarian cancer
cases and 324 cancer-free controls. The genotype distri-
butions of the p73 (rs4648551 G > A, rs6695978 G > A)
and p63 (rs873330 T > C) polymorphisms between the
case and control groups are shown in Table 2. We con-
cluded that the frequency of the A allele in p73
rs6695978 G > A was statistically higher in the case
group compared with the control group. Women with
the A allele were at increased risk of ovarian cancer
compared to carriers of the G allele (OR = 1.55; 95% CI:
1.07-2.19; P = 0.003). Of interesting, we found that the
at-risk A allele in rs6695978 G > A was significantly
associated with ovarian cancer in the allele dose–
response manner. That is, carrying the GA and AA gen-
otypes may increase ovarian cancer susceptibility by
1.64-fold (95% CI: 1.37-1.95; P = 0.004) and 1.81-foldTable 2 Logistic regression analyses on associations between
ovarian cancer





rs873330 T > C TT 182 (56.7)
TC 118 (36.8)
CC 21 (6.5)
T allele 482 (75.1)
C allele 160 (24.9)
p73
rs4648551 G > A GG 316 (97.5)
GA 8 (2.5)
AA 0 (0.0)
G allele 640 (98.8)
A allele 8 (1.2)
rs6695978 G > A GG 240 (74.1)
GA 73 (22.5)
AA 11 (3.4)
G allele 553 (85.3)
A allele 95 (14.7)
a. OR and 95% CI represent odds ratios and 95% confidence intervals from logistic
use, cigarette smoking, ovarian cancer family history.
All statistical tests were two-sided with a significance level of P ≤ 0.05.(95% CI: 1.56-2.14; P = 0.004) compared with the GG
genotype respectively. The data in Table 2 indicated that
no associations of p63 rs873330 T > C and p73
rs4648551 G > A with ovarian cancer pathogenesis were
found. In summary, we determined that the rs6695978
A allele may be the at-risk allele for ovarian cancer, sug-
gesting that carriers of the A allele may be more suscep-
tible to ovarian cancer among Chinese women.
The p73 rs6695978 G > A SNP was positively associated
with known clinicopathological variables.
Considering that none of the investigated SNPs except
the p73 rs6695978 G > A had shown an association be-
tween the case group and the control group, we merely
listed the data between the rs6695978 G > A genotype
frequencies and the clinicopathological characteristics,
including age at diagnosis, tumor histology, degree of
differentiation, clinical stage , tumor behavior, lymph
node status, estrogen receptor (ER) and progesterone re-
ceptor (PR) status (Table 3). The results from the logistic
regression models revealed that the A allele was posi-
tively associated with the occurrence of mucinous ovar-
ian cancer (OR = 3.48; 95% CI:1.15-6.83; P = 0.001), low
degree of differentiation (OR = 1.87; 95% CI:1.03-3.47;
P = 0.003), lymph node metastasis (OR = 1.69; 95% CI:
1.14-2.75; P = 0.010) and ER positive (OR = 2.72; 95% CI:
1.38-4.81; P = 0.002), which can be used to predictp63 rs873330, p73 rs4648551, rs6695978 and risk of
ubjects (%) Adjusteda
Cases P OR (95 % CI)
160 (52.0) 0.142 1.00 (ref)
122 (39.6) 1.15 (0.88-1.52)
26 (8.4) 1.21 (0.78-1.89)
442 (71.8)
174 (28.2) 0.098 1.16 (0.79-1.68)
296 (96.1) 0.936 1.00 (ref)
10 (3.3) 1.05 (0.91-1.22)
2 (0.6)
602 (97.7)
14 (2.3) 0.558 1.41 (0.99-1.93)
198 (64.3) 0.004 1.00 (ref)
94 (30.5) 1.64 (1.37-1.95)
16 (5.2) 1.81 (1.56-2.14)
490 (79.5)
126 (20.5) 0.003 1.55 (1.07-2.19)
regression analysis, adjusted for age, BMI, number liveborn, oral contraceptive




All Genotype(%) A allele
frequency
Adjusteda
GG GA+AA P OR (95 % CI)
Age 308 0.948
< 52 118 88 (74.6) 30 (25.4) 0.136 1.00 (ref)
≥52 190 146 (76.8) 44 (23.2) 0.137 2.87 (0.93-5.84)
Clinical stage 300 0.474
I-II 92 69 (75.0) 23 (25.0) 0.131 1.00 (ref)
III-IV 208 158 (76.0) 50 (24.0) 0.142 1.30 (0.89-1.93)
Tumor histology 308 0.003
Serous 196 150 (76.5) 46 (23.5) 0.128 1.00 (ref)
Mucinous 24 15 (62.5) 9 (37.5) 0.250 0.001 3.48 (1.15-6.83)
Endometrioid 22 17 (77.3) 5 (22.7) 0.114 0.337 2.25 (0.96-4.44)
Mixed/other 66 52 (78.8) 14 (21.2) 0.136 0.597 0.93 (0.76-1.19)
Degree of differentiation 246 0.005
High 28 22 (78.6) 6 (21.4) 0.107 1.00 (ref)
Medium 82 65 (79.3) 17 (20.7) 0.104 0.827 1.15 (0.86-1.69)
Low 136 98 (72.1) 38 (27.9) 0.162 0.003 1.87 (1.03-3.47)
Tumor behavior 294 0.838
Borderline 48 37 (77.1) 11 (22.9) 0.125 1.00 (ref)
Invasive 246 191 (77.6) 55 (22.4) 0.122 0.91 (0.79-1.03)
Lymph node statusb 176 0.010
Negative 62 50 (80.6) 12 (19.4) 0.105 1.00 (ref)
Positive 114 83 (72.8) 31 (27.2) 0.154 1.69 (1.14-2.75)
ERc 183 0.002
Negative 42 36 (85.7) 6 (14.3) 0.095 1.00 (ref)
Positive 141 100 (70.9) 41 (29.1) 0.163 2.72 (1.38-4.81)
PRc 171 0.329
Negative 66 49 (74.2) 17 (25.8) 0.144 1.00 (ref)
Positive 105 81 (77.1) 24 (22.9) 0.129 1.43 (0.76-2.32)
a Logistic regression model adjusted for age, BMI, number liveborn, oral contraceptive use, cigarette smoking, ovarian cancer family history.
b For advanced ovarian cancer patients, in terms of primary cytoreductive surgery, whether to simultaneously apply pelvic and para-aortic lymph node dissection
is controversial. The general consensus that pelvic and para-aortic lymph node dissection does not increase the 5-year survival rate and improve prognosis has
been widely accepted. Thus, some patients involved in our study only underwent primary cytoreductive surgery without pelvic and para-aortic lymph node
dissection. The data regarding lymph node status in patients were partially missing.
c Unlike breast cancer and endometrial cancer, the significance of ER and PR in the clinical treatment and prognosis of ovarian cancer is also valuable and
disputed. Meanwhile, combined with the economic condition of the patients, some cases did not undergo ER and PR immunohistochemical analyses.
All statistical tests were two-sided with a significance level of P ≤ 0.05.
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our analysis did not show significant associations of the
polymorphism with age at diagnosis, clinical stage,
tumor behavior and PR status. Therefore, the p73
rs6695978 G > A polymorphism may be a potential indi-
cator of clinical prognosis in Chinese female ovarian
cancer patients.
Discussion
Recent studies have revealed that several genetic poly-
morphisms may play important roles in the pathogenesisof ovarian cancer [14,15], and women who carried the
gene mutation (BRCA1 mutation) had an increased risk
(by up to 50%) of developing ovarian cancer in a lifetime
[16]. In one of the most recent genome-wide association
study (GWAS) conducted in ovarian cancer, a strong asso-
ciation with 12 single-nucleotide polymorphisms (SNPs)
in the Basonuclin 2 (BNC2) gene was found, where the
minor allele of the associated SNPs were protective against
disease[17,18]. Moreover, a meta-analysis showed that
patients with one of single nuclear polymorphisms vitamin
D receptor (VDR), the FokI rs2228570 TT genotype, had a
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well as prostate, breast, skin, non-Hodgkin lymphoma,
and colorectal cancer compared with its CC genotype
[19,20]. By seeking susceptibility genes and establishing
high-risk populations, early diagnosis may be beneficial to
improve ovarian cancer survival.
As tumor candidate genes, p63 and p73 are involved in
the regulation of the cell cycle, apoptosis, differentiation
and other critical cellular processes. The abnormal expres-
sion of the two genes can play catalytic roles in the devel-
opment of ovarian tumors and achieve synergy in terms of
early malignant transformation and enhanced tumor inva-
sion. In recent years, there has been an increased interest
in research into the connection between p63 and p73 var-
iants generated by genetic polymorphisms and cancer pro-
gression. Meanwhile, several genetic polymorphisms have
been implicated in the pathogenesis of ovarian cancer
[14-20]. However, little is known about how the p63 and
p73 polymorphisms are involved in ovarian cancer suscep-
tibility and clinical pathology. Therefore, we conducted
this study to genotype three SNPs in the p63 and p73
genes to determine whether this polymorphism func-
tioned as a modifier of ovarian cancer development.
Prior studies have demonstrated that p63 and p73
were highly expressed in female germ cells during
meiotic arrest and play an important role in DNA
damage-induced apoptosis in female germ cells [21,22].
Recently, three SNPs (rs873330 T > C, rs4648551 G > A,
rs6695978 G > A) located in p63 and p73 were identified,
and they appear to be under evolutionary selection pres-
sures using the criteria of Atwal[23,24] and information
theory. That study showed a clear enrichment of the
SNPs in infertility and IVF patients and revealed that
polymorphisms in the human p63 and p73 genes could
be involved in reproductive deficits [11,25]. In theory,
the factors including non-pregnancy, infertility and ap-
plication of ovulation induction drugs that lead to con-
tinued ovulation can increase the incidence of ovarian
cancer [26]. Infertility therapies utilize products, such as
IVF, that alter the hormonal balance and may also in-
crease the risk of ovarian tumors [12]. Based on the
close relationship between infertility and ovarian cancer
susceptibility, we genotyped these SNPs in ovarian can-
cer patients and normal individuals using a case–control
study. Our results indicated that the A allele frequency
in p73 rs6695978 G > A was statistically higher in the
case group compared with the control group. Women
with the A allele were at increased risk of ovarian cancer
compared to carriers of the G allele, which also con-
firmed that this polymorphism may serve as a predictor
of ovarian cancer susceptibility.
Ovarian cancers comprise a broad spectrum of malig-
nancies, ranging from serous to mucinous, endometrioid,
clear cell and other histologic subtypes. These histotypeshave been recently associated with distinct molecular pro-
files and polymorphisms, supporting the idea that the dis-
tinct molecular pathways and genotype may strongly
affect germinal histotypes in ovarian cancer [27-30]. As
demonstrated in our research, the frequencies of A allele
and combined GA+AA genotypes in p73 rs6695978 G >A
were statistically elevated in mucinous ovarian cancer com-
pared with other subtypes. In all histologic types, the prog-
nosis of mucinous ovarian cancer is unsatisfactory and
prone to metastasis and drug resistance [31], which intro-
duces difficulties and challenges into clinical treatment.
The median survival (MS) of mucinous adenocarcinomas
did not differ significantly between the groups interpreted
as primary or metastatic, but the overall survival (OS) of
mucinous adenocarcinomas is significantly less than that
for women with serous carcinoma [32]. Mucinous carcin-
omas are independent predictors of poor prognosis in stage
III/IV ovarian cancer [33]. Consequently, our study indi-
cates that the rs6695978 A allele may be more closely
related to the occurrence of mucinous ovarian cancer and
individuals carrying the AA and GA genotypes may suffer
from poorer prognoses.
With respect to the clinical stage, differentiation de-
gree and lymph node status in ovarian cancer, which can
guide clinical treatment and outcomes, there is also
mounting evidence that p73 protein expression may play
a vital role in malignant transformation, clinical stage,
differentiation degree and metastasis of ovarian cancer
[34]. The lower the differentiation degree, the higher the
level of p73 expression. Increasing the expression of the
p73 protein in tumor cells may strengthen the suppres-
sion of cellular apoptosis; the survivability and malig-
nancy of the tumor are enhanced accordingly. Thus,
tumor cells may have an easier time to invade the sur-
rounding tissues and metastasize to the lymph nodes,
which shorten the survival of ovarian cancer patients. In
this study, we clarified the association of the A allele fre-
quency in the p73 rs6695978 G > A with a low degree of
differentiation and lymph node metastasis, which is simi-
lar to what was seen in previous studies on the status of
p73 expression in ovarian cancer. However, the biological
relevance for an association between rs6695978 A allele
and ovarian cancer remains unclear. Therefore, we will
sought to assess whether there was a necessary link be-
tween p73 expression status and the p73 rs6695978 G >
A polymorphism in the next step. Further investigation
in a larger sample size involved molecular mechanisms
are indispensable.
Ovarian cancer is a hormone-dependent malignancy,
and estrogen/ progesterone and its receptors may play
important roles in the pathogenesis of ovarian cancer.
For a long time, progesterone has been considered to be
a protective factor for ovarian cancer. Approximately
26% to 49% of ovarian cancers have PR expression [35],
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good prognosis [36]. In contrast, estrogen has been con-
sidered as a risk factor for epithelial ovarian cancer. The
proliferation of ovarian tissue with estrogenic stimula-
tion and estrogen/hormone replacement therapy (HRT)
may possibly increase the risk of ovarian cancer [37,38].
Approximately 61% to 79% of ovarian cancers express
the ER [35]. From the pathological standpoint, estrogen
and ER expression can accelerate the mitosis of ovarian
cancer cells, which rely on inhibiting apoptosis and pro-
moting cell proliferation to participate in the develop-
ment of tumors. Hence, ER-positive ovarian cancer
patients often suffer from a poor prognosis. The data in
our research illustrated that ER-positive patients tend to
carry the AA and GA genotypes in p73 rs6695978 com-
pared with the GG genotypes. In contrast with ER-
negative, the A allele frequency in rs6695978 were also
statistically increased in ER-positive patients. There
appears to be a potential connection between rs6695978
A allele and bad clinical outcomes.
In conclusion, this is the first study to indicate the p73
rs6695978 G > A A allele as the at-risk allele may en-
hance susceptibility to ovarian cancer in Chinese
women. The individuals with the A allele were at
increased risk of ovarian cancer compared to carriers of
the G allele, and positively associated with the occur-
rence of mucinous ovarian cancer, poor differentiation,
lymph node metastasis and estrogen receptor status,
which all indicate a poor prognosis for ovarian cancer.
However, detailed ovarian tumor histology data were not
available, and the biological and mechanistic relevances
between rs6695978 A allele and ovarian cancer remain
unclear. Meanwhile, the process of ovarian cancer devel-
opment in women is probably mediated by other candi-
date genotypes and different pathways; this analysis
leads to future work in the following directions (a) with
large samples and detailed surveys focusing on the func-
tional pattern of this polymorphism (b) examination of
p73 expression levels by genotype among the current
population. (c) analysis of genotypic interactions with
closely-related genes. Further research of this critical
gene and those which are biologically related may lead
to a better informed biological understanding of ovarian
cancers. Substantiating its independent prognostic value
for clinical diagnosis and outcome is of great signifi-
cance. In addition, findings such as these will lead to the
development of genetic risk prediction panels for even-
tual classification of women who may most benefit from
targeted surveillance or prevention strategies.
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